Donepezil
E133125
Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
All labels observed (5)
| Label | Occurrences |
|---|---|
| Aricept | 3 |
| Donepezil canonical | 2 |
| Aricept ODT | 1 |
| Donepezil – Alzheimer’s disease | 1 |
| donepezil | 1 |
Statements (62)
| Predicate | Object |
|---|---|
| instanceOf |
acetylcholinesterase inhibitor
ⓘ
cholinesterase inhibitor ⓘ medication ⓘ piperidine derivative ⓘ |
| approvedBy |
Food and Drug Administration
ⓘ
surface form:
U.S. Food and Drug Administration
|
| ATCCode | N06DA02 ⓘ |
| canBeUsedWith | memantine ⓘ |
| cautionIn |
patients with COPD
ⓘ
patients with asthma ⓘ patients with bradycardia ⓘ patients with cardiac conduction abnormalities ⓘ patients with peptic ulcer disease ⓘ |
| chemicalFormula | C24H29NO3 ⓘ |
| coMarketedBy | Pfizer ⓘ |
| commonSideEffect |
anorexia
ⓘ
diarrhea ⓘ fatigue ⓘ insomnia ⓘ muscle cramps ⓘ nausea ⓘ vomiting ⓘ |
| contraindication | hypersensitivity to donepezil ⓘ |
| crosses | blood–brain barrier ⓘ |
| developedBy | Eisai ⓘ |
| doesNotCure | Alzheimer's disease ⓘ |
| dosageForm |
oral tablet
ⓘ
orally disintegrating tablet ⓘ |
| effect | slows cognitive decline in Alzheimer's disease ⓘ |
| eliminationHalfLife | about 70 hours ⓘ |
| FDAApprovalYear | 1996 ⓘ |
| hasBrandName |
Donepezil
self-linksurface differs
ⓘ
surface form:
Aricept
Donepezil self-linksurface differs ⓘ
surface form:
Aricept ODT
|
| hasGenericName | donepezil ⓘ |
| hasHigherDoseStrength | 23 mg once daily ⓘ |
| hasINN |
Donepezil
self-linksurface differs
ⓘ
surface form:
donepezil
|
| hasMolecularWeight | 379.50 g/mol ⓘ |
| hasUSAN | donepezil ⓘ |
| increasesLevelOf | acetylcholine in the brain ⓘ |
| isListedOn | World Health Organization Model List of Essential Medicines ⓘ |
| isSelectiveFor | central nervous system acetylcholinesterase ⓘ |
| legalStatusEU | prescription only ⓘ |
| legalStatusUS | prescription only ⓘ |
| mechanismOfAction | reversible inhibition of acetylcholinesterase ⓘ |
| metabolizedBy |
CYP2D6
ⓘ
CYP3A4 ⓘ |
| pregnancyCategoryUS | C ⓘ |
| proteinBinding | high ⓘ |
| routeOfAdministration | oral ⓘ |
| seriousSideEffect |
bradycardia
ⓘ
gastrointestinal bleeding ⓘ seizures ⓘ syncope ⓘ |
| taken |
once daily
ⓘ
usually at bedtime ⓘ |
| treats |
Alzheimer's disease
ⓘ
mild Alzheimer's disease ⓘ moderate Alzheimer's disease ⓘ severe Alzheimer's disease ⓘ |
| typicalMaintenanceDose | 5–10 mg once daily ⓘ |
| typicalStartingDose | 5 mg once daily ⓘ |
| usedFor |
cognitive symptoms of Alzheimer's disease
ⓘ
dementia associated with Alzheimer's disease ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Donepezil Description of subject: Donepezil is a cholinesterase inhibitor medication primarily used to treat cognitive symptoms of Alzheimer's disease.
Referenced by (8)
Full triples — surface form annotated when it differs from this entity's canonical label.
this entity surface form:
Aricept
this entity surface form:
Donepezil – Alzheimer’s disease
this entity surface form:
Aricept
this entity surface form:
Aricept ODT